Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout

Inclusion Criteria: * with informed consent; * Ages 18-65; * Overweight/obesity: BMI ≥24kg/m2; * A history of gout with serum uric acid levels of \> 420μmol/L in men and postmenopausal women, and \>360 μmol/L in premenopausal women; * Moderate or above fatty liver was found in the initial screening by ultrasound, and the liver fat content was more than 15% as determined by MRI-PDFF. Exclusion Criteria: * with a history of allergy to febuxostat and allopurinol; * in the acute active phase of gout; * Drinking equivalent to alcohol intake ≥30g/d(male), ≥20g/d(female); * Patients with obvious abnormal liver function: serum transaminase (ALT, AST, GGT one of them) or serum bilirubin (direct bilirubin, indirect bilirubin one of them) exceed 2 times the upper limit of normal reference value; Serum albumin \<35g/L; * Have a history of viral hepatitis, or serological examination suggests hepatitis virus infection, or have a history of other liver diseases; * Complicated with renal insufficiency (SCr \>133μmol/L) or urinary protein +; * Complicated coronary heart disease; * Cardiac dysfunction (cardiac function grade 2 or above); * Complementation with diabetes, or fasting blood glucose \>7.8mmol/L, or HbA1c \>7.5%; * Severe hypertension, blood pressure ≥ 160/100 mmHg; * Patients with asthma and other respiratory diseases; * Intestinal diseases such as inflammatory bowel disease; * Any history of systemic malignancy in the past 5 years; * Morbid obesity (BMI\>37.5kg/m2); * Triglyceride ≥5.0 mmol/L was found to be significantly abnormal in baseline examination; * had received systemic hormone or immunosuppressive therapy within 3 months prior to screening, or expected to receive hormone or immunosuppressive therapy in the future; * Use of uric-lowering drugs in the 4 weeks before screening: febuxostat, benzobromarone, allopurinol; * Use of other drugs affecting uric acid metabolism were adjusted within 4 weeks before screening: losartan, fenofibrate, irbesartan, thiazide diuretics, loop medullaral diuretics, compound antihypertensive agents containing diuretics; * Other drugs that may affect liver fat content were taken within 4 weeks before screening; * Weight change ≥5% within 3 months before screening; * Women who are lactating or pregnant or who plan to become pregnant within one year; * were enrolled in other studies within 6 months before screening; * unsuitable for participants to participate in this study.